A phase I, open-label, dose-escalation study to assess the safety and tolerability of AT9283, a selective small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2009
At a glance
- Drugs AT 9283 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jun 2009 Results presented at ASCO 2009.
- 16 May 2009 Status changed from not stated to completed.
- 01 Dec 2006 New trial record.